Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 19

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 19
---
 supplement
for general corporate purposes, including working capital,
operating expenses, and capital expenditures,
as described in the section of this prospectus
supplement entitled “Use of P roceeds.”
We will have broad
discretion in the application of the net proceeds
in the category of general corporate purposes
and investors will be relying on the judgment of our management regarding
the application of the proceeds of this offering.

The precise amount and timing
of the application of these proceeds, if any,
will depend upon a number of factors, such as our funding requirements
and the availability and costs of other funds. As of the date
of this prospectus supplement, we cannot specify with
certainty all of the particular uses for the net
proceeds to us from this offering. Depending on the outcome of our efforts
and other unforeseen events, our plans and priorities
may change and we may apply the net proceeds of this
offering in different manners than we currently
anticipate.

The failure by our management
to apply these funds effectively
could harm our business, financial condition
and results of operations. Pending their use, we may invest the net proceeds
from this offering in short-term, interest-bearing
instruments. These investments may not yield a favorable return to our stockholders.

The actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain.

Subject to certain limitations
in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the sales agents at
any time throughout the term of the Sales Agreement. The number of shares that are sold by the sales agents after delivering a placement
notice will fluctuate based on the market price of our Common Stock during the sales period and limits we set with the sales agents. Because
the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not
possible at this stage to predict the number of shares that will be ultimately issued or the aggregate proceeds to be raised in connection
with sales under the Sales Agreement.

<div align='center'>S-11</div>

The Common Stock o ffered hereby will be sold in “at the market” o fferings, and investors who buy shares at di fferent times will l ikely pay di fferent prices.

Investors who purchase
shares in this offering at different
times will likely pay different
prices, and so